Share Name Share Symbol Market Type Share ISIN Share Description
Intelligent Ultrasound Group Plc LSE:MED London Ordinary Share GB00BN791Q39 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 14.50 0.00 01:00:00
Bid Price Offer Price High Price Low Price Open Price
14.00 15.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 5.92 -4.56 -2.37 39
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 14.50 GBX

Intelligent Ultrasound (MED) Latest News

More Intelligent Ultrasound News
Intelligent Ultrasound Investors    Intelligent Ultrasound Takeover Rumours

Intelligent Ultrasound (MED) Discussions and Chat

Intelligent Ultrasound Forums and Chat

Date Time Title Posts
13/1/202109:45Medaphor Group PLC 109
10/7/201907:57MEDAPHOR thread9
24/10/201215:08MicroEmissive Displays - LCD Replacement Technology !787
01/12/200410:57MicroEmissve Displays - LCD Replacement Technology !-
12/2/200312:42media stocks armageddon1

Add a New Thread

Intelligent Ultrasound (MED) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Intelligent Ultrasound trades in real-time

Intelligent Ultrasound (MED) Top Chat Posts

Intelligent Ultrasound Daily Update: Intelligent Ultrasound Group Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker MED. The last closing price for Intelligent Ultrasound was 14.50p.
Intelligent Ultrasound Group Plc has a 4 week average price of 0p and a 12 week average price of 0p.
The 1 year high share price is 16.25p while the 1 year low share price is currently 10.25p.
There are currently 269,396,792 shares in issue and the average daily traded volume is 0 shares. The market capitalisation of Intelligent Ultrasound Group Plc is £39,062,534.84.
40 fathoms: Timbo003, well spotted indeed. My own view is with respect to COVID and be it Caption or MED, AI powered lung ultrasound has missed the boat and is probably not going to become a major revenue source for either.
w t tutte: I agree it really is astonishing. The concern always in a situation like this is someone comes along and scoops the company up for a song. With the IP Group in such a dominant position on the shareholder register that is much less of a worry. If GE or someone approached, you can be sure they would only be tempted at a price that was some function of fair value. In the meantime more for us to nibble away at !
chillpill: Barely anyone follows MED. Number of people watching their YouTube clips is very low.
babbler: Lol iqai got FDA and triples. Med does nada.
w t tutte: Never any drama with MED they just get on with it. Quality Company in just the right area and completely ignored by the market. This is a complete head scratcher to me.
w t tutte: You could not want for a better partner and it is good to see that in the marketing of the new product the AI aspects are very prominent. I have been looking at MED for about a year now and so far I have to say I am impressed with how management have delivered on key milestones within their predicted time targets.
40 fathoms: It is amazing that this business is not more widely followed. If they are going to hit their first revenue targets from ScanNav then we should be getting an announcement on who the OEM partner is in the next month or so. Also, as you pointed out, very hard to pick up stock without putting upward pressure on the share price. There are very few sellers in the market. To my mind this is clearly a stock with multi bagger potential.
callumross: What a trap this share is for PI's. A seller only got 7.25p for a five grand transaction when the bid price is 10p!
tullynessle: Another Non-Regulatory RNS today Medaphor Group PLC AI database exceeds 1 million images 27 November 2018 MedaPhor Group plc ("MedaPhor" or the "Company") MedaPhor's AI obstetric image database exceeds 1 million images MedaPhor, the intelligent ultrasound software and simulation company, is pleased to announce that its database used for training its artificial intelligence (AI) products now exceeds 1 million obstetric ultrasound images. Large image libraries are a prerequisite to creating AI solutions. These images have helped MedaPhor to develop its ScanNav(R) AI-based clinical software for ultrasound professionals. The one million mark is a significant milestone for the Company, as it will enable it to build on its ScanNav software for the global obstetric ultrasound market. MedaPhor's ScanNav intelligent ultrasound technology, which uses AI algorithms and deep learning techniques to automatically assess ultrasound images, is currently being piloted in UK hospitals to support sonographers carrying out the 20 week anatomy scan. ScanNav assists sonographers to ensure that the images they are taking conform to the UK Fetal Anomaly Screening Programme (FASP) protocol. In future, the software will also be capable of automatically recording required images during the ultrasound scan. Continued.........
tullynessle: RNS Non-Regulatory today. Medaphor Group PLC MedaPhor commences clinical trial for AnatomyGuide 23/11/2018 3:56pm RNS Non-Regulatory MedaPhor commences clinical trial for AnatomyGuide MedaPhor (AIM:MED), the intelligent ultrasound software and simulation company, announces it is commencing a clinical trial within the Aneurin Bevan University Health Board to capture data for its AnatomyGuide artificial intelligence (AI) software for ultrasound-guided anaesthetic procedures such as peripheral nerve blocks. Increasingly, ultrasound-guided peripheral nerve blocks are being used as a safer and more cost-effective alternative to general anaesthesia but not all anaesthetists have the specialist knowledge of ultrasound anatomy to perform them. AnatomyGuide provides software support and guidance to aid less experienced clinicians during the procedure. Using deep-learning techniques on a data set of thousands of real-patient images, the technology is 'taught' to recognise key anatomical structures. Then, by highlighting these structures in real-time during an ultrasound-guided nerve block procedure, AnatomyGuide's AI makes it easier for clinicians to accurately target the nerve. The clinical data from the Aneurin Bevan clinical trial is expected to complete the required data set. Through the adoption of AnatomyGuide, it is hoped that hospitals will be able to increase the number of ultrasound-guided nerve blocks that they can perform. Principal Investigator and consultant anaesthetist, Dr David Burckett-St.Laurent, said: "AnatomyGuide will help tip the balance of safety and confidence in favour of performing regional anaesthesia. I feel privileged to work with a Welsh company that is leading the world in developing AI-based ultrasound software. Our aim is to make a real clinical difference to patients by increasing the availability of regional anaesthesia through cutting edge technology. It is very exciting." AnatomyGuide is being developed as part of an Innovate UK project funded within the government's AI and data grand challenge. Nicholas Sleep, CTO at MedaPhor, commented: "AnatomyGuide shows how strategic government investment can catalyse an innovative technology that we hope will make a real difference to NHS patient care. The team in Cardiff are excited to be working with Innovate UK in developing AI technology that has real-world applications and we look forward to completing the clinical trials with David and the Aneurin Bevan University Health Board."
Intelligent Ultrasound share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210621 04:12:52